Ascletis Pharma has dosed the first subject in the Phase II clinical trial of ASC22 (Envafolimab) plus anti-retroviral therapy (ART) for immune restoration/ functional cure of human immunodeficiency virus 1 (HIV-1) infection in China.

Given subcutaneously, ASC22 is a single domain antibody against programmed death-ligand 1 (PD-L1). 

It could potentially restore virus-specific immune responses in people with chronic viral infection. 

The randomised, placebo-controlled, single-blind, multicentre trial will analyse the safety and efficacy of ASC22 to treat HIV-1 infection versus placebo, along with ART during a 12-week treatment and 12-week follow-up period.

The company plans to conclude the trial earlier next year and will enrol nearly 30 subjects.

Participants in the ASC22 group will be given subcutaneous doses of 1mg/kg or 2.5mg/kg plus standard ART including integrase inhibitors (INSTIs) once every four weeks (Q4W) for 12 weeks. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Subjects in the placebo arm will receive 0.9% saline plus ART Q4W for 12 weeks. 

The primary outcome measures of the trial are variation in CD4/CD8 ratio from baseline recorded at weeks 4, 8 and 12.

Ascletis Pharma founder, chairman and CEO Dr Jinzi Wu said: “By blocking PD-1/PD-L1 pathway, ASC22 is expected to potentially restore HIV-1 specific immunity and clear the latent HIV reservoir. 

“We will accelerate the clinical study of ASC22 and share more milestones in the near future.”

Apart from the immune restoration/functional cure indication for HIV-1, the company developed another indication of ASC22 as a functional cure for chronic hepatitis B.

In April this year, Ascletis reported that its oral small molecule drug candidate, ASC11, demonstrated the potential to treat Covid-19.